Award-wining architecture firm Ashton Raggatt McDougall and its former boss have agreed to pay a combined $975,000 in penalties for attempting to rig bids on a $250 million building project at Charles Darwin University.
A court has heard that a director at office leasing company Cushman & Wakefield who accepted a job with a competitor could lose a $1.3 million sign-on bonus if the case by her former employer is not promptly resolved.
BlueScope Steel spent $27 million defending the ACCC’s claims that it engaged in serious cartel conduct in relation to the supply of flat steel products in Australia, and its apologies came too late to warrant a penalty discount, a court has heard.
Crikey publisher Private Media has filed a new contextual truth defence to defamation claims brought by Lachlan Murdoch, arguing the Fox News CEO is “morally and ethically culpable” for the January 6 riot on the US Capitol.
Bayer told a jury that clinical trials from the 1990’s to 2014 showed its Essure birth control device was “safe and efficacious”, as the pharmaceutical giant faces trial in a class action by patients who claim they suffered debilitating injuries from the device.
Spain has lost its High Court appeal arguing it had sovereign immunity from an Australian court’s recognition of a $394 million arbitration award against the country for changes to its energy policies.
Accused rapist Bruce Lehrmann will learn this week whether his defamation cases against News Corp and Network Ten can proceed despite the expiration of a 12-month limitations period.
The maker of Finish dishwashing detergent has taken Procter & Gamble to court, arguing it misled consumers by claiming its Fairy 30 Minute Miracle dish detergent is more effective than the competition.
A judge has rejected a Federal Circuit and Family Court judge’s decision to transfer a PhD student’s Fair Work lawsuit against the University of Western Australia to the Federal Court because his court does not have the proper resources to consider it.
Pharmaceutical giant Bayer cannot write off debilitating chronic pain and bleeding which patients allegedly experienced after being implanted with Essure contraceptives as “common women’s symptoms”, a court has heard in the first day of trial in a long-running class action.